 |
| 메디톡스 전경 (사진=메디톡스) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Medytox announced on the 7th that its operating profit rose 35% year-on-year to 46.7 billion won last year.
Sales reached 195.1 billion won last year, up 6% over the same period. Net profit fell 60% to 37.6 billion won due to the base effect of temporary profits reflected in the settlement of contract termination. In the fourth quarter of last year, it achieved sales of 52.3 billion won and operating profit of 16.3 billion won.
Medytox explained that the high growth of its flagship businesses such as botulinum toxin and filler drove its performance. Toxin sales grew 99% and 26% overseas and domestically, respectively. Sales in the filler sector also rose 29 percent and 24 percent, respectively, overseas and in Korea.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
